Related references
Note: Only part of the references are listed.Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates
Danny Hung-Chieh Chou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
Eduardo Martinez de Duenas et al.
BREAST (2014)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
M. A. Province et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen
Christos Markopoulos et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
Hiltrud Brauch et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical and biomarker predictors of side effects from tamoxifen
Wendy Lorizio et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study
Hadine Joffe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Boronate-Mediated Biologic Delivery
Gregory A. Ellis et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer
Quan Jiang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Adherence to long-term adjuvant hormonal therapy for breast cancer
Carolyn Gotay et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2011)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Monique J. Bijl et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
CYP2D6 and tamoxifen: DNA matters in breast cancer
Janelle M. Hoskins et al.
NATURE REVIEWS CANCER (2009)
A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women
Robert Mansel et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation
Yan Zheng et al.
DRUG METABOLISM AND DISPOSITION (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib
V Uttamsingh et al.
DRUG METABOLISM AND DISPOSITION (2005)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Boronic acid compounds as potential pharmaceutical agents
WQ Yang et al.
MEDICINAL RESEARCH REVIEWS (2003)